Michael P. Bonk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michael P. Bonk has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Nuala J. Meyer
Division of Pulmonary, Allergy, and Critical Care Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA
3 shared publications - Brian J. Anderson
Assistant Professor of Medicine, Hospital of the University of Pennsylvania, 3400 Spruce Street, 5036 Gates Building, Philadelphia, PA 19104, USA
2 shared publications - Denis Hadjiliadis
University of Pennsylvania, 3400 Spruce St, Philadelphia, PA 19104, USA
2 shared publications - Jason D. Christie
Perelman School of Medicine at the University of Pennsylvania , Philadelphia, PA
2 shared publications John P. Reilly
Division of Pulmonary, Allergy, and Critical Care, Department of Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania
2 shared publications- Brian Lim
Department of Cardiothoracic and Vascular Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York
1 shared publication
Latest Publications
- Open Access
- 11 July 2024
- Published by California Digital Library (CDL) in Clinical Practice and Cases in Emergency Medicine
- Vol. 8 (3) , 197-201
Capnocytophaga ochracea Septicemia After a Dog Bite: The Case of a Usual Suspect Transmitting an Unusual Organism
Introduction: Capnocytophaga ochracea is found in the human oral microbiome and is a rare cause of antibiotic-resistant, opportunistic septicemia in immunocompromised hosts. The zoonotic transmission of C ochracea from canines to humans has not yet been reported in the literature. Cohabitation with people is associated with oral colonization in dogs and may be a reservoir for Capnocytophaga infections, which have a decreased susceptibility to first-line antibiotics commonly used to treat animal exposures. Case Report: This is the case of a 70-year-old male with a remote history of lymphoma status post splenectomy, in remission, who presented with stigmata of Capnocytophaga septicemia after a dog bite, which included purpura fulminans on physical examination. Initial broad-spectrum coverage with cefepime failed to slow the progression into multiorgan failure. A Capnocytophaga strain with extended resistance was suspected. Antibiotics were transitioned to meropenem, and the patient eventually made a good recovery. Blood cultures isolated C ochracea. Conclusion: Capnocytophaga infections should be suspected in patients with severe sepsis and purpura fulminans after a canine exposure. Canine pets may be a reservoir for Capnocytophaga species with increased antibiotic resistances, such as C ochracea, which trace their origins to the human oral microbiome. A thorough medical history is essential to identify risk factors such as asplenia and active immune compromise that are associated with infections from antibiotic-resistant strains and worse outcomes. For Capnocytophaga infections that fail initial therapies, cephalosporins should be avoided because of high resistance rates, and the use of carbapenems may be favored over combination beta-lactam/beta-lactamase inhibitors in select clinical scenarios.
- 11 July 2024
- Published by California Digital Library (CDL) in Clinical Practice and Cases in Emergency Medicine
- Vol. 8 (3) , 197-201
Open AccessCapnocytophaga ochracea Septicemia After a Dog Bite: The Case of a Usual Suspect Transmitting an Unusual Organism
Introduction: Capnocytophaga ochracea is found in the human oral microbiome and is a rare cause of antibiotic-resistant, opportunistic septicemia in immunocompromised hosts. The zoonotic transmission of C ochracea from canines to humans has not yet been reported in the literature. Cohabitation with people is associated with oral colonization in dogs and may be a reservoir for Capnocytophaga infections, which have a decreased susceptibility to first-line antibiotics commonly used to treat animal exposures. Case Report: This is the case of a 70-year-old male with a remote history of lymphoma status post splenectomy, in remission, who presented with stigmata of Capnocytophaga septicemia after a dog bite, which included purpura fulminans on physical examination. Initial broad-spectrum coverage with cefepime failed to slow the progression into multiorgan failure. A Capnocytophaga strain with extended resistance was suspected. Antibiotics were transitioned to meropenem, and the patient eventually made a good recovery. Blood cultures isolated C ochracea. Conclusion: Capnocytophaga infections should be suspected in patients with severe sepsis and purpura fulminans after a canine exposure. Canine pets may be a reservoir for Capnocytophaga species with increased antibiotic resistances, such as C ochracea, which trace their origins to the human oral microbiome. A thorough medical history is essential to identify risk factors such as asplenia and active immune compromise that are associated with infections from antibiotic-resistant strains and worse outcomes. For Capnocytophaga infections that fail initial therapies, cephalosporins should be avoided because of high resistance rates, and the use of carbapenems may be favored over combination beta-lactam/beta-lactamase inhibitors in select clinical scenarios.
- 4 January 2021
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 131 (1)
The ABO histo-blood group, endothelial activation, and acute respiratory distress syndrome risk in critical illness
BACKGROUND. The ABO histo-blood group is defined by carbohydrate modifications and is associated with risk for multiple diseases, including acute respiratory distress syndrome (ARDS). We hypothesized that genetically determined blood subtype A1 is associated with increased risk of ARDS and markers of microvascular dysfunction and coagulation. METHODS. We conducted analyses in 3 cohorts of critically ill trauma and sepsis patients (n = 3710) genotyped on genome-wide platforms to determine the association of the A1 blood type genotype with ARDS risk. We subsequently determined whether associations were present in FUT2-defined nonsecretors who lack ABO antigens on epithelium, but not endothelium. In a patient subgroup, we determined the associations of blood type with plasma levels of endothelial glycoproteins and disseminated intravascular coagulation (DIC). Lastly, we tested whether blood type A was associated with less donor lung injury recovery during human ex vivo lung perfusion (EVLP). RESULTS. The A1 genotype was associated with a higher risk of moderate to severe ARDS relative to type O in all 3 populations. In sepsis, this relationship was strongest in nonpulmonary infections. The association persisted in nonsecretors, suggesting a vascular mechanism. The A1 genotype was also associated with higher DIC risk as well as concentrations of thrombomodulin and von Willebrand factor, which in turn were associated with ARDS risk. Blood type A was also associated with less lung injury recovery during EVLP. CONCLUSION. We identified a replicable association between ABO blood type A1 and risk of ARDS among the critically ill, possibly mediated through microvascular dysfunction and coagulation. FUNDING. NIH HL122075, HL125723, HL137006, HL137915, DK097307, HL115354, HL101779, and the University of Pennsylvania McCabe Fund Fellowship Award.
- 4 January 2021
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 131 (1)
The ABO histo-blood group, endothelial activation, and acute respiratory distress syndrome risk in critical illness
BACKGROUND. The ABO histo-blood group is defined by carbohydrate modifications and is associated with risk for multiple diseases, including acute respiratory distress syndrome (ARDS). We hypothesized that genetically determined blood subtype A1 is associated with increased risk of ARDS and markers of microvascular dysfunction and coagulation. METHODS. We conducted analyses in 3 cohorts of critically ill trauma and sepsis patients (n = 3710) genotyped on genome-wide platforms to determine the association of the A1 blood type genotype with ARDS risk. We subsequently determined whether associations were present in FUT2-defined nonsecretors who lack ABO antigens on epithelium, but not endothelium. In a patient subgroup, we determined the associations of blood type with plasma levels of endothelial glycoproteins and disseminated intravascular coagulation (DIC). Lastly, we tested whether blood type A was associated with less donor lung injury recovery during human ex vivo lung perfusion (EVLP). RESULTS. The A1 genotype was associated with a higher risk of moderate to severe ARDS relative to type O in all 3 populations. In sepsis, this relationship was strongest in nonpulmonary infections. The association persisted in nonsecretors, suggesting a vascular mechanism. The A1 genotype was also associated with higher DIC risk as well as concentrations of thrombomodulin and von Willebrand factor, which in turn were associated with ARDS risk. Blood type A was also associated with less lung injury recovery during EVLP. CONCLUSION. We identified a replicable association between ABO blood type A1 and risk of ARDS among the critically ill, possibly mediated through microvascular dysfunction and coagulation. FUNDING. NIH HL122075, HL125723, HL137006, HL137915, DK097307, HL115354, HL101779, and the University of Pennsylvania McCabe Fund Fellowship Award.
- Open Access
- 1 October 2019
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 16 (10) , 1337-1338
Reply: Against Another Nonspecific Marker of Perfusion
- 1 October 2019
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 16 (10) , 1337-1338
Open AccessReply: Against Another Nonspecific Marker of Perfusion
- 1 May 2019
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 16 (5) , 552-553
Troponin I: A New Marker of Sepsis-induced Hypoperfusion?
- 1 May 2019
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 16 (5) , 552-553
Troponin I: A New Marker of Sepsis-induced Hypoperfusion?
- 1 February 2019
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 16 (2) , 197-199
Clear as Mud: Diagnostic Uncertainty in Acute Respiratory Distress Syndrome
- 1 February 2019
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 16 (2) , 197-199
Clear as Mud: Diagnostic Uncertainty in Acute Respiratory Distress Syndrome
- 27 January 2019
- Published by Annual Reviews in Annual Review of Medicine
- Vol. 70 (1) , 197-210
Cystic Fibrosis: Emerging Understanding and Therapies
Cystic fibrosis (CF) is the most common life-limiting genetic disease in Caucasian patients. Continued advances have led to improved survival, and adults with CF now outnumber children. As our understanding of the disease improves, new therapies have emerged that improve the basic defect, enabling patient-specific treatment and improved outcomes. However, recurrent exacerbations continue to lead to morbidity and mortality, and new pathogens have been identified that may lead to worse outcomes. In addition, new complications, such as CF-related diabetes and increased risk of gastrointestinal cancers, are creating new challenges in management. For patients with end-stage disease, lung transplantation has remained one of the few treatment options, but challenges in identifying the most appropriate patients remain.
- 27 January 2019
- Published by Annual Reviews in Annual Review of Medicine
- Vol. 70 (1) , 197-210
Cystic Fibrosis: Emerging Understanding and Therapies
Cystic fibrosis (CF) is the most common life-limiting genetic disease in Caucasian patients. Continued advances have led to improved survival, and adults with CF now outnumber children. As our understanding of the disease improves, new therapies have emerged that improve the basic defect, enabling patient-specific treatment and improved outcomes. However, recurrent exacerbations continue to lead to morbidity and mortality, and new pathogens have been identified that may lead to worse outcomes. In addition, new complications, such as CF-related diabetes and increased risk of gastrointestinal cancers, are creating new challenges in management. For patients with end-stage disease, lung transplantation has remained one of the few treatment options, but challenges in identifying the most appropriate patients remain.
- 1 October 2018
- Published by Elsevier in Journal of Critical Care
- Vol. 47, 324-330
Quantitative peripheral muscle ultrasound in sepsis: Muscle area superior to thickness
- 1 October 2018
- Published by Elsevier in Journal of Critical Care
- Vol. 47, 324-330
Quantitative peripheral muscle ultrasound in sepsis: Muscle area superior to thickness
- 1 November 2017
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 16 (6) , 647-648
New Comorbidities in the Changing Face of Cystic Fibrosis Care
- 1 November 2017
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 16 (6) , 647-648
New Comorbidities in the Changing Face of Cystic Fibrosis Care
- 1 January 2017
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 16 (1) , 24-29
Therapeutic benefit observed with the CFTR potentiator, ivacaftor, in a CF patient homozygous for the W1282X CFTR nonsense mutation
- 1 January 2017
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 16 (1) , 24-29
Therapeutic benefit observed with the CFTR potentiator, ivacaftor, in a CF patient homozygous for the W1282X CFTR nonsense mutation